Your browser doesn't support javascript.
loading
Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study.
Armario, Xavier; Carron, Jennifer; Simpkin, Andrew J; Elhadi, Mohamed; Kennedy, Ciara; Abdel-Wahab, Mohamed; Bleiziffer, Sabine; Lefèvre, Thierry; Wolf, Alexander; Pilgrim, Thomas; Villablanca, Pedro A; Blackman, Daniel J; Van Mieghem, Nicolas M; Hengstenberg, Christian; Swaans, Martin J; Prendergast, Bernard D; Patterson, Tiffany; Barbanti, Marco; Webb, John G; Behan, Miles; Resar, Jon; Chen, Mao; Hildick-Smith, David; Spence, Mark S; Zweiker, David; Bagur, Rodrigo; Teles, Rui; Ribichini, Flavio L; Jagielak, Dariusz; Park, Duk-Woo; Kornowski, Ran; Wykrzykowska, Joanna J; Bunc, Matjaz; Estévez-Loureiro, Rodrigo; Poon, Karl; Götberg, Matthias; Jeger, Raban V; Ince, Hüseyin; Packer, Erik J S; Angelillis, Marco; Nombela-Franco, Luis; Guo, Yingqiang; Savontaus, Mikko; Al-Moghairi, Abdulrahman M; Parasca, Catalina Andreea; Kliger, Chad; Roy, David; Molnár, Levente; Silva, Mariana; White, Jonathon.
Affiliation
  • Armario X; Department of Cardiology, Galway University Hospital, Galway, Ireland; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Carron J; Department of Cardiology, Galway University Hospital, Galway, Ireland.
  • Simpkin AJ; School of Mathematical and Statistical Sciences, University of Galway, Galway, Ireland.
  • Elhadi M; Department of Cardiology, Galway University Hospital, Galway, Ireland.
  • Kennedy C; Department of Cardiology, Galway University Hospital, Galway, Ireland.
  • Abdel-Wahab M; Heart Center Leipzig, Leipzig, Germany.
  • Bleiziffer S; Heart and Diabetes Center Northrhine-Westfalia, Clinic for Thoracic and Cardiovascular Surgery, Bad Oeynhausen, Germany.
  • Lefèvre T; Institut Cardiovasculaire Paris Sud, Massy, France.
  • Wolf A; Elisabeth-Krankenhaus Essen, Essen, Germany.
  • Pilgrim T; Bern University Hospital, Bern, Switzerland.
  • Villablanca PA; Henry Ford Hospital, Detroit, Michigan, USA.
  • Blackman DJ; Leeds General Infirmary, Leeds, United Kingdom.
  • Van Mieghem NM; Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Hengstenberg C; General Hospital of Vienna, Medical University, Vienna, Austria.
  • Swaans MJ; St. Antonius Hospital, Nieuwegein, Netherlands.
  • Prendergast BD; St Thomas' Hospital, London, United Kingdom.
  • Patterson T; St Thomas' Hospital, London, United Kingdom.
  • Barbanti M; Università degli Studi di Enna Kore, Enna, Italy.
  • Webb JG; St. Paul's Hospital, Vancouver, British Columbia, Canada.
  • Behan M; Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
  • Resar J; John Hopkins Hospital, Baltimore, Maryland, USA.
  • Chen M; West China Hospital, Sichuan University, Chengdu, China.
  • Hildick-Smith D; Royal Sussex County Hospital, Brighton, United Kingdom.
  • Spence MS; Royal Victoria Hospital, Belfast, United Kingdom.
  • Zweiker D; Medical University of Graz, Graz, Austria.
  • Bagur R; University Hospital, London Health Sciences Center, London, Ontario, Canada.
  • Teles R; Hospital de Santa Cruz, CHLO, Nova Medical School, CEDOC, Lisbon, Portugal.
  • Ribichini FL; Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Jagielak D; Medical University of Gdansk, Gdansk, Poland.
  • Park DW; Asan Medical Center, Seoul, South Korea.
  • Kornowski R; Rabin Medical Center, Petah Tikva, Israel.
  • Wykrzykowska JJ; University Medical Center Groningen, Groningen, the Netherlands.
  • Bunc M; Ljubljana University Medical Center, Ljubljana, Slovenia.
  • Estévez-Loureiro R; Hospital Universitario Álvaro Cunqueiro, Vigo, Spain.
  • Poon K; The Prince Charles Hospital, Brisbane, Australia.
  • Götberg M; Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden.
  • Jeger RV; Basel University Hospital, Basel, Switzerland.
  • Ince H; University Medicine Rostock, Rostock, Germany.
  • Packer EJS; Haukeland University Hospital, Bergen, Norway.
  • Angelillis M; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Nombela-Franco L; Hospital Clínico San Carlos, Madrid, Spain.
  • Guo Y; West China Hospital, Sichuan University, Chengdu, China.
  • Savontaus M; Turku University Hospital, Turku, Finland.
  • Al-Moghairi AM; Prince Sultan Cardiac Center, Riyadh, Saudi Arabia.
  • Parasca CA; Emergency Institute for Cardiovascular Diseases, Bucharest, Romania.
  • Kliger C; Lenox Hill/Northwell Health, New York, New York, USA.
  • Roy D; St. Vincent's Hospital, Sydney, Australia.
  • Molnár L; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Silva M; Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
  • White J; Auckland City Hospital, Auckland, New Zealand.
JACC Cardiovasc Interv ; 17(3): 374-387, 2024 Feb 12.
Article in En | MEDLINE | ID: mdl-38180419
ABSTRACT

BACKGROUND:

The COVID-19 pandemic adversely affected health care systems. Patients in need of transcatheter aortic valve replacement (TAVR) are especially susceptible to treatment delays.

OBJECTIVES:

This study sought to evaluate the impact of the COVID-19 pandemic on global TAVR activity.

METHODS:

This international registry reported monthly TAVR case volume in participating institutions prior to and during the COVID-19 pandemic (January 2018 to December 2021). Hospital-level information on public vs private, urban vs rural, and TAVR volume was collected, as was country-level information on socioeconomic status, COVID-19 incidence, and governmental public health responses.

RESULTS:

We included 130 centers from 61 countries, including 65,980 TAVR procedures. The first and second pandemic waves were associated with a significant reduction of 15% (P < 0.001) and 7% (P < 0.001) in monthly TAVR case volume, respectively, compared with the prepandemic period. The third pandemic wave was not associated with reduced TAVR activity. A greater reduction in TAVR activity was observed in Africa (-52%; P = 0.001), Central-South America (-33%; P < 0.001), and Asia (-29%; P < 0.001). Private hospitals (P = 0.005), urban areas (P = 0.011), low-volume centers (P = 0.002), countries with lower development (P < 0.001) and economic status (P < 0.001), higher COVID-19 incidence (P < 0.001), and more stringent public health restrictions (P < 0.001) experienced a greater reduction in TAVR activity.

CONCLUSIONS:

TAVR procedural volume declined substantially during the first and second waves of the COVID-19 pandemic, especially in Africa, Central-South America, and Asia. National socioeconomic status, COVID-19 incidence, and public health responses were associated with treatment delays. This information should inform public health policy in case of future global health crises.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aortic Valve Stenosis / Transcatheter Aortic Valve Replacement / COVID-19 Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: JACC Cardiovasc Interv Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2024 Document type: Article Affiliation country: España

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aortic Valve Stenosis / Transcatheter Aortic Valve Replacement / COVID-19 Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: JACC Cardiovasc Interv Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2024 Document type: Article Affiliation country: España